Integra LifeSciences Holdings (IART) - Total Assets
Based on the latest financial reports, Integra LifeSciences Holdings (IART) holds total assets worth $3.58 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Integra LifeSciences Holdings reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Integra LifeSciences Holdings - Total Assets Trend (1995–2025)
This chart illustrates how Integra LifeSciences Holdings's total assets have evolved over time, based on quarterly financial data. Explore Integra LifeSciences Holdings strategic investment ratio to see how much of total assets are deployed in long-term investments.
Integra LifeSciences Holdings - Asset Composition Analysis
Current Asset Composition (December 2025)
Integra LifeSciences Holdings's total assets of $3.58 Billion consist of 32.2% current assets and 67.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.5% |
| Accounts Receivable | $278.85 Million | 7.7% |
| Inventory | $492.74 Million | 13.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.13 Billion | 31.5% |
| Goodwill | $615.16 Million | 17.1% |
Asset Composition Trend (1995–2025)
This chart illustrates how Integra LifeSciences Holdings's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Integra LifeSciences Holdings.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Integra LifeSciences Holdings's current assets represent 32.2% of total assets in 2025, a decrease from 47.9% in 1995.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2025, down from 23.2% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is intangible assets at 31.5% of total assets.
Integra LifeSciences Holdings Competitors by Total Assets
Key competitors of Integra LifeSciences Holdings based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Integra LifeSciences Holdings - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.38 | 1.06 | 3.24 |
| Quick Ratio | 1.95 | 0.57 | 2.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $825.17 Million | $52.71 Million | $713.63 Million |
Integra LifeSciences Holdings - Advanced Valuation Insights
This section examines the relationship between Integra LifeSciences Holdings's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.27 |
| Latest Market Cap to Assets Ratio | 0.37 |
| Asset Growth Rate (YoY) | -10.8% |
| Total Assets | $3.60 Billion |
| Market Capitalization | $1.32 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Integra LifeSciences Holdings's assets below their book value (0.37x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Integra LifeSciences Holdings's assets decreased by 10.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Integra LifeSciences Holdings (1995–2025)
The table below shows the annual total assets of Integra LifeSciences Holdings from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.60 Billion | -10.78% |
| 2024-12-31 | $4.04 Billion | +6.75% |
| 2023-12-31 | $3.78 Billion | -2.77% |
| 2022-12-31 | $3.89 Billion | +2.84% |
| 2021-12-31 | $3.78 Billion | +4.63% |
| 2020-12-31 | $3.62 Billion | +9.44% |
| 2019-12-31 | $3.30 Billion | +6.29% |
| 2018-12-31 | $3.11 Billion | -3.22% |
| 2017-12-31 | $3.21 Billion | +77.62% |
| 2016-12-31 | $1.81 Billion | +1.87% |
| 2015-12-31 | $1.77 Billion | +12.42% |
| 2014-12-31 | $1.58 Billion | +31.97% |
| 2013-12-31 | $1.20 Billion | +2.80% |
| 2012-12-31 | $1.16 Billion | +1.70% |
| 2011-12-31 | $1.14 Billion | +12.46% |
| 2010-12-31 | $1.02 Billion | +8.21% |
| 2009-12-31 | $940.10 Million | -9.12% |
| 2008-12-31 | $1.03 Billion | +26.46% |
| 2007-12-31 | $818.01 Million | +33.31% |
| 2006-12-31 | $613.62 Million | +36.84% |
| 2005-12-31 | $448.43 Million | -1.81% |
| 2004-12-31 | $456.71 Million | +10.71% |
| 2003-12-31 | $412.53 Million | +50.19% |
| 2002-12-31 | $274.67 Million | +20.69% |
| 2001-12-31 | $227.59 Million | +163.06% |
| 2000-12-31 | $86.51 Million | +30.49% |
| 1999-12-31 | $66.30 Million | +91.07% |
| 1998-12-31 | $34.70 Million | -9.64% |
| 1997-12-31 | $38.40 Million | -21.15% |
| 1996-12-31 | $48.70 Million | +151.03% |
| 1995-12-31 | $19.40 Million | -- |
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural … Read more